Globus Medical, Inc. logo GMED - Globus Medical, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 26
HOLD 9
SELL 1
STRONG
SELL 0
| PRICE TARGET: $102.38 DETAILS
HIGH: $117.00
LOW: $80.00
MEDIAN: $101.50
CONSENSUS: $102.38
UPSIDE: 34.69%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 85% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Undervalued Moderate
Trading 31.9% below fair value
Current Price $76.01
Bear Case $76.18 0.2% upside ($76.18 - $76.01) / $76.01 = 0.2% 8% stage 1 growth, 11% discount
Fair Value $111.63 46.9% upside ($111.63 - $76.01) / $76.01 = 46.9% 13% stage 1 growth, 11% discount
Bull Case $149.42 96.6% upside ($149.42 - $76.01) / $76.01 = 96.6% 17% stage 1 growth, 11% discount

Adjust Assumptions

13.2%
11.0%
3.0%

Key Value Driver

FCF growth rate (13% base case)

Terminal Value % of EV 41%
Implied Market Multiple 17.8x
Market is pricing in (growth) 7.4% vs our 13.2% base

Plain-Language Summary

Our base-case estimate uses a two-stage discounted cash flow model based on free cash flow. We then blend that result with the average analyst price target of $102.38 from 36 analysts, using a 30% weight on analyst consensus. That produces an estimated intrinsic value of $111.63 per share.

Key Risks

  • P/E alone misleads — earnings depressed by growth investment
  • Cyclical or commodity businesses may be misclassified as platforms
  • Terminal value dominance suggests sensitivity to long-run assumptions